200 related articles for article (PubMed ID: 23575351)
1. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
Liu XJ; Wu WT; Wu WH; Yin F; Ma SH; Qin JZ; Liu XX; Liu YN; Zhang XY; Li P; Han S; Liu KY; Zhang JM; He QH; Shen L
CNS Neurosci Ther; 2013 Jul; 19(7):494-502. PubMed ID: 23575351
[TBL] [Abstract][Full Text] [Related]
2. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
[TBL] [Abstract][Full Text] [Related]
4. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
5. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.
Emlet DR; Gupta P; Holgado-Madruga M; Del Vecchio CA; Mitra SS; Han SY; Li G; Jensen KC; Vogel H; Xu LW; Skirboll SS; Wong AJ
Cancer Res; 2014 Feb; 74(4):1238-49. PubMed ID: 24366881
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Joo KM; Kim SY; Jin X; Song SY; Kong DS; Lee JI; Jeon JW; Kim MH; Kang BG; Jung Y; Jin J; Hong SC; Park WY; Lee DS; Kim H; Nam DH
Lab Invest; 2008 Aug; 88(8):808-15. PubMed ID: 18560366
[TBL] [Abstract][Full Text] [Related]
10. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
12. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Griffero F; Daga A; Marubbi D; Capra MC; Melotti A; Pattarozzi A; Gatti M; Bajetto A; Porcile C; Barbieri F; Favoni RE; Lo Casto M; Zona G; Spaziante R; Florio T; Corte G
J Biol Chem; 2009 Mar; 284(11):7138-48. PubMed ID: 19147502
[TBL] [Abstract][Full Text] [Related]
13. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
[TBL] [Abstract][Full Text] [Related]
15. Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Kunimasa K; Nagano T; Shimono Y; Dokuni R; Kiriu T; Tokunaga S; Tamura D; Yamamoto M; Tachihara M; Kobayashi K; Satouchi M; Nishimura Y
Cancer Sci; 2017 Jul; 108(7):1368-1377. PubMed ID: 28445002
[TBL] [Abstract][Full Text] [Related]
16. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo.
Tirino V; Desiderio V; Paino F; De Rosa A; Papaccio F; Fazioli F; Pirozzi G; Papaccio G
FASEB J; 2011 Jun; 25(6):2022-30. PubMed ID: 21385990
[TBL] [Abstract][Full Text] [Related]
17. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
18. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
Hidayat M; Mitsuishi Y; Takahashi F; Tajima K; Yae T; Miyahara K; Hayakawa D; Winardi W; Ihara H; Koinuma Y; Wirawan A; Nurwidya F; Kato M; Kobayashi I; Sasaki S; Takamochi K; Hayashi T; Suehara Y; Moriyama M; Moriyama H; Habu S; Takahashi K
Bosn J Basic Med Sci; 2019 Nov; 19(4):355-367. PubMed ID: 31202256
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
20. CD133 expression in chemo-resistant Ewing sarcoma cells.
Jiang X; Gwye Y; Russell D; Cao C; Douglas D; Hung L; Kovar H; Triche TJ; Lawlor ER
BMC Cancer; 2010 Mar; 10():116. PubMed ID: 20346143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
